WO2004050837A3 - Treatment of dna damage related disorders - Google Patents

Treatment of dna damage related disorders Download PDF

Info

Publication number
WO2004050837A3
WO2004050837A3 PCT/US2003/037838 US0337838W WO2004050837A3 WO 2004050837 A3 WO2004050837 A3 WO 2004050837A3 US 0337838 W US0337838 W US 0337838W WO 2004050837 A3 WO2004050837 A3 WO 2004050837A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
related disorders
dna damage
damage related
chloroquine
Prior art date
Application number
PCT/US2003/037838
Other languages
French (fr)
Other versions
WO2004050837A2 (en
Inventor
Michael B Kastan
Christopher J Bakkenist
Original Assignee
St Jude Childrens Res Hospital
Michael B Kastan
Christopher J Bakkenist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/307,077 external-priority patent/US7108992B2/en
Application filed by St Jude Childrens Res Hospital, Michael B Kastan, Christopher J Bakkenist filed Critical St Jude Childrens Res Hospital
Priority to US10/496,685 priority Critical patent/US20050124653A1/en
Priority to AU2003293099A priority patent/AU2003293099A1/en
Publication of WO2004050837A2 publication Critical patent/WO2004050837A2/en
Publication of WO2004050837A3 publication Critical patent/WO2004050837A3/en
Priority to US11/473,415 priority patent/US20060241139A1/en
Priority to US12/334,209 priority patent/US20090099134A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides methods and compositions for the treatment of DNA damage related disorders. One embodiment of the invention is a prophylactic method for the prevention of cancer using a chloroquine compound. Another embodiment is a method for the inhibition of side effects associated with chemotherapeutic and radiotherapeutic agents using chloroquine compounds.
PCT/US2003/037838 2002-11-27 2003-11-26 Treatment of dna damage related disorders WO2004050837A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/496,685 US20050124653A1 (en) 2002-11-27 2003-11-26 Treatment of dna damage related disorders
AU2003293099A AU2003293099A1 (en) 2002-11-27 2003-11-26 Treatment of dna damage related disorders
US11/473,415 US20060241139A1 (en) 2002-11-27 2006-06-23 Treatment of DNA damage related disorders
US12/334,209 US20090099134A1 (en) 2002-11-27 2008-12-12 Treatment of dna damage related disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/307,077 2002-11-27
US10/307,077 US7108992B2 (en) 2002-11-27 2002-11-27 ATM kinase compositions and methods
US10/351,733 US6916627B2 (en) 2002-11-27 2003-01-24 ATM kinase compositions and methods
US10/351,733 2003-01-24

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US10/307,077 Continuation-In-Part US7108992B2 (en) 2002-11-27 2002-11-27 ATM kinase compositions and methods
US10/307,077 Continuation US7108992B2 (en) 2002-11-27 2002-11-27 ATM kinase compositions and methods
US10/351,733 Continuation-In-Part US6916627B2 (en) 2002-11-27 2003-01-24 ATM kinase compositions and methods

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10496685 A-371-Of-International 2003-11-26
US10/856,343 Continuation-In-Part US20050032834A1 (en) 2002-11-27 2004-05-27 Treatment of DNA damage related disorders
US10/857,167 Continuation-In-Part US20050014785A1 (en) 2002-11-27 2004-05-27 Treatment of radiation disorders

Publications (2)

Publication Number Publication Date
WO2004050837A2 WO2004050837A2 (en) 2004-06-17
WO2004050837A3 true WO2004050837A3 (en) 2006-04-06

Family

ID=32474121

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/037838 WO2004050837A2 (en) 2002-11-27 2003-11-26 Treatment of dna damage related disorders
PCT/US2003/038091 WO2004050842A2 (en) 2002-11-27 2003-11-26 Atm kinase compositions and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/038091 WO2004050842A2 (en) 2002-11-27 2003-11-26 Atm kinase compositions and methods

Country Status (3)

Country Link
US (7) US6916627B2 (en)
AU (2) AU2003297595A1 (en)
WO (2) WO2004050837A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
EP1694322A2 (en) * 2003-11-26 2006-08-30 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
WO2007059372A2 (en) 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
WO2007075655A2 (en) 2005-12-19 2007-07-05 Northwestern University Compositions and methods for altering rnai
EP1881080A1 (en) * 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
EP2156179B1 (en) * 2007-04-04 2021-08-18 The Regents of The University of California Methods for using a nanopore
WO2009047567A1 (en) * 2007-10-10 2009-04-16 University Of Sheffield Assay for identifying agents which inhibit the atr and/or dna-pk pathways
US8957031B2 (en) 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
CA2730773A1 (en) * 2008-07-14 2010-01-21 Martha Karen Newell Methods and products for treating proliferative diseases
WO2010117715A1 (en) * 2009-03-30 2010-10-14 George Mason Intellectual Properties, Inc. Malignant precursor cells from ductal carcinoma in situ lesions
US8716307B2 (en) * 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
KR101128058B1 (en) 2009-10-15 2012-04-12 한국원자력의학원 Composition comprising tolnaftate for inhibiting ATM kinase
AU2015216822A1 (en) 2014-02-17 2016-09-01 Centre Leon Berard Predictive method of characterizing the radiosensitivity and tissular reaction of a patient to therapeutic ionizing radiation
WO2019059943A1 (en) * 2017-09-25 2019-03-28 Obi Justice E Compositions and methods for treatment of bowen's disease and related diseases
CN109797128A (en) * 2019-01-14 2019-05-24 浙江大学 A kind of construction method of acute cell iron overload model
CN112553274B (en) * 2020-12-02 2023-06-13 江南大学 Method for cutting DNA by soybean extract Bowman-Birk inhibitor
WO2023152668A1 (en) * 2022-02-14 2023-08-17 Università Degli Studi Di Urbino Carlo Bo Variants of the human atm protein for the treatment of diseases related to at least one mutation of the atm gene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340803A (en) * 1991-11-04 1994-08-23 Co Enzyme Technology Ltd. Method and compositions for treating tumors having high tyrosinase activity
US20020044919A1 (en) * 2000-01-19 2002-04-18 Baofa Yu Combinations and methods for treating neoplasms

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2233970A (en) * 1941-03-04 Quinoline compound and process of
US3127401A (en) * 1964-03-31 Z-benzyl-j
NL130759C (en) * 1965-10-07
US3663693A (en) * 1967-03-16 1972-05-16 Sterling Drug Inc Antimalarial compositions and methods of their use
US3689646A (en) * 1969-09-04 1972-09-05 Univ Pennsylvania Antimutagenic treatment of bacteria
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
DE2748333A1 (en) * 1977-10-28 1979-05-03 Hoechst Ag AGENT AGAINST MALARIA
US4431807A (en) * 1980-06-12 1984-02-14 The United States Of America As Represented By The Secretary Of The Army 4-Methyl-5-(unsubstituted and substituted phenoxy)-6-methoxy-8-(aminoalkylamino)quinolines
FR2498187A1 (en) * 1981-01-16 1982-07-23 Rhone Poulenc Sante PROCESS FOR THE PREPARATION OF AMINO-4 CHLORO-7 QUINOLINES
US5278173A (en) * 1988-06-30 1994-01-11 Davis Michael H Method of inhibiting the activity of human immunodeficiency virus (HIV) in vivo
ZA899033B (en) * 1988-12-01 1990-09-26 Merrell Dow Pharma Phenoxy and phenylthio,amino substituted benzocycloalkane derivatives in the treatment and prevention of drug-resistant protozoal infections
US5668149A (en) * 1990-01-26 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of human immunodeficiency virus-1 infectivity in human cells
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5430039A (en) * 1990-09-28 1995-07-04 Cephalon, Inc. Treatment of neurological disorders
JPH06505991A (en) * 1991-02-25 1994-07-07 デビオファルム　ソシエテ　アノニム Drugs to suppress multidrug resistance in cancer
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
CA2117913C (en) 1992-04-10 2006-05-09 Richard J. Epstein Activation-state-specific phosphoprotein immunodetection
US5314894A (en) * 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
US5340603A (en) 1993-08-30 1994-08-23 Abbott Laboratories Nutritional product for human infants having chronic lung disease
CA2133620A1 (en) * 1993-10-28 1995-04-29 Werner Hofheinz Aminoquinoline derivatives
US5639761A (en) * 1994-02-14 1997-06-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof
US5665359A (en) * 1994-04-29 1997-09-09 Ho; Walter Kwok Keung Method and compositions for lowering blood lipids
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
TR199800854T2 (en) * 1995-11-16 1998-08-21 F.Hoffmann-La Roche Ag Antis�tma quinoline turret.
AU8068198A (en) 1997-06-13 1998-12-30 President And Fellows Of Harvard College Methods for treating human cancers
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6387640B1 (en) 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6348311B1 (en) 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
WO2001003649A2 (en) * 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease
KR100390332B1 (en) 2000-08-02 2003-07-07 유원민 anti-cancer composition composed of anti-cancer and anti-malarial drugs
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
EP1408972A2 (en) 2001-07-23 2004-04-21 Epidauros Biotechnologie AG Methods for treatment of cancer with irinotecan based on mdr1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340803A (en) * 1991-11-04 1994-08-23 Co Enzyme Technology Ltd. Method and compositions for treating tumors having high tyrosinase activity
US20020044919A1 (en) * 2000-01-19 2002-04-18 Baofa Yu Combinations and methods for treating neoplasms

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIELICKY ET AL: "Chloroquine Diphosphate and Whole Body Irradiation strahlentherapie", vol. 133, no. 2, June 1967 (1967-06-01), pages 307 - 311 *
COBREROS ET AL: "Modifiers of Radiation Action on DNA Screened by Analytical Ultracentrifugation", RADIATION RESEARCH, vol. 92, no. 2, 1982, pages 255 - 267, XP008062141 *
HAGIHARA ET AL: "Vascular Protection by Chloroquine during Brain Tumor Therapy with Tf-CRM107", CANCER RESEARCH, vol. 60, 15 January 2000 (2000-01-15), pages 230 - 234, XP002994590 *
KAWANISHI ET AL: "Mechanism of guanine-specific DNA damage by oxidative stress and its role in carcinogenesis and aging", MUTATION RESEARCH, vol. 488, no. 1, 2001, pages 65 - 76, XP008062135 *
OIKAWA ET AL: "Site-Specific DNA Damage at the GGG Sequence by UVA Involves Acceleration of Telomere Shortening", BIOCHEMISTRY, vol. 40, 2001, pages 4763 - 4768, XP002994591 *
SJOLIN-FORSBERG ET AL: "Topical chloroquine applied before irradiation protects against ultraviolet B (UVB)- and UVA-induced erythema but not against immediate pigment darkening", PHOTODERMATOL PHOTOIMMUNOL PHOTOMED, vol. 9, no. 5, October 1992 (1992-10-01) - October 1993 (1993-10-01), pages 220 - 224, XP008062144 *
ZEILHOFER ET AL, CANCER LETTERS, vol. 44, no. 1, January 1989 (1989-01-01), pages 61 - 66, XP002994589 *

Also Published As

Publication number Publication date
AU2003293099A8 (en) 2004-06-23
US6916627B2 (en) 2005-07-12
WO2004050837A2 (en) 2004-06-17
US20030157572A1 (en) 2003-08-21
WO2004050842A2 (en) 2004-06-17
AU2003297595A1 (en) 2004-06-23
AU2003293099A1 (en) 2004-06-23
US20070009919A1 (en) 2007-01-11
US20080020462A1 (en) 2008-01-24
US20090099134A1 (en) 2009-04-16
US20050032834A1 (en) 2005-02-10
US20060241139A1 (en) 2006-10-26
US7160692B2 (en) 2007-01-09
AU2003297595A8 (en) 2004-06-23
WO2004050842A3 (en) 2005-08-11
US7279290B2 (en) 2007-10-09
US20050148020A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
WO2004050837A3 (en) Treatment of dna damage related disorders
WO2002030353A3 (en) NF-λB INHIBITORS
WO2001005390A3 (en) Method for treating chronic pain using mek inhibitors
PL369292A1 (en) Adhesion inhibition of fungi
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2004053087A3 (en) Nf-κb inhibitors
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
WO2004032908A3 (en) Method of inhibiting angiogenesis
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
GB2389532B (en) The method of treating cancer
AU2002308642A1 (en) Methods for treating cancer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2002320352A1 (en) Methods for treating or preventing sclerotic disorders using cd2-binding agents
WO2002083151A3 (en) Compositions and methods for treating an arthritic condition
WO2003028642A3 (en) Methods of inhibiting metastases
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies
AU2001243248A1 (en) Method for the prevention or reduction of vascular access dysfunction
AU2003300551A8 (en) Compounds for the inhibition of non-proteolytic enzymes
AU2003284787A1 (en) Inhibitor of angiogenesis and kit for treating cancer comprising the inhibitor
AU2003212990A1 (en) Novel compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
AU2004311370A1 (en) Methods and compositions for the inhibition of cathepsins
WO2000017133A3 (en) Lta4 hydrolase inhibitors
IL160242A0 (en) Methods for the treatment and prognosis of leukemia and other cancer types

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10496685

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)